| 000 | 01633 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515095048.0 | ||
| 264 | 0 | _c20080403 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a8755-6863 | ||
| 024 | 7 |
_a10.1002/ppul.20736 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRetsch-Bogart, George Z | |
| 245 | 0 | 0 |
_aA phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. _h[electronic resource] |
| 260 |
_bPediatric pulmonology _cJan 2008 |
||
| 300 |
_a47-58 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Inhalation |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAztreonam _xadministration & dosage |
| 650 | 0 | 4 |
_aCystic Fibrosis _xcomplications |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aForced Expiratory Flow Rates |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNebulizers and Vaporizers |
| 650 | 0 | 4 |
_aPseudomonas Infections _xcomplications |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBurns, Jane L | |
| 700 | 1 | _aOtto, Kelly L | |
| 700 | 1 | _aLiou, Theodore G | |
| 700 | 1 | _aMcCoy, Karen | |
| 700 | 1 | _aOermann, Christopher | |
| 700 | 1 | _aGibson, Ronald L | |
| 773 | 0 |
_tPediatric pulmonology _gvol. 43 _gno. 1 _gp. 47-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ppul.20736 _zAvailable from publisher's website |
| 999 |
_c17556173 _d17556173 |
||